The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for
branded medicines pricing on Thursday (4 May).
A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023
In their first meeting, the government, NHS England and industry - represented by the ABPI -expected to agree to a shared negotiation aim of working toward a
mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth.
Health Minister, Will Quince, said: "These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our
health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times - one of the Prime Minister's 5 priorities.
The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life
sciences sector.
US biotech firm Moderna will build a new research and manufacturing centre in Britain to develop vaccines against new Covid-19 variants, other respiratory
illnesses and help improve readiness for any future pandemics.
The facility is expected to start producing shots in 2025 and Britain has made a commitment to buy Moderna's vaccines for the next decade under the agreement.
Moderna's Covid-19 vaccines, which use messenger RNA (mRNA) technology, were among those deployed in Britain to tackle the crisis and enable prime minister Boris
Johnson to reopen the economy from stringent lockdowns.
Moderna chief executive Stephane Bancel said the priority was to develop a shot combining refreshed boosters against Covid, flu and Respiratory Syncytial Virus (RSV).
"By building a plant in the UK, we are also providing the UK Government - which has a long term partnership with us, with this agreement - with the ability to be
pandemic ready," Bancel said on Wednesday.
Pharmaceutical companies AbbVie and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday.
Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors as repayment rates in
2023 have surged to 26.5 per cent of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement.
"The current scheme has harmed innovation, with costs spiralling out of control, and the UK falling behind other major countries to be left as a global outlier,"
said Laura Steele, president and general manager for Eli Lilly's Northern Europe division.
ABPI said it was seeking early talks with the government to set out a new future settlement.
In December, the industry body had said the government raised the amount manufacturers of branded medicines within the voluntary scheme will be required to return
to almost £3.3 billion in sales revenue from an earlier amount of £1.8 billion.
Former superintendent pharmacist and National Pharmacy Association (NPA) director, Phil Galt, has been appointed the new UK managing director for pharmacy
software supplier Cegedim Rx.
The position was previously held by Adam Dennett, who resigned after a successful ten-year tenure to pursue a new career outside healthcare, the company said.
Cegedim Rx, the pharmacy entity of Cegedim Healthcare Solutions UK, announced the new appointment this month (April 5).
Tristan de Foucher, head of European operations for Cegedim Group, said: "Adam has been a force of nature in this business for the past 10 years. Under his
leadership, the team has continuously and successfully invested in and driven product innovation to stay ahead of the ever-changing demands placed upon community
pharmacy."
Galt has over 20 years of experience as a qualified pharmacist and a successful business leader. He has worked extensively in community pharmacy, focusing on
both care delivery and technology implementation.
The UK government has pledged £133m to healthcare innovation funding, which will help boost the country's innovations in medical imaging and artificial intelligence (AI), among other areas.
The UK Government is investing £100 million to accelerate the use of AI in life sciences and healthcare under a new mission.
UK Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission in his speech last week.
The new initiative will capitalise on the UK's unique strengths in securing "health data and cutting-edge AI."
It will also help to identify those at risk of "dementia" and will ensure that patients participate in the trials at the right time to develop new treatments
effectively.
Henceforth, it will provide us with better data on how well new therapies work.
Sunak said: "AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer."
Haleon, the consumer healthcare giant behind brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut down its Maidenhead
manufacturing site in the UK.
This decision will impact 435 employees and comes as part of a broader strategic realignment of the company's global manufacturing operations according to BBC.
The Maidenhead facility, which has been in operation for years, manufactures some of Haleon's most popular oral health products, including Sensodyne and Parodontax.
However, following a comprehensive review of its manufacturing capabilities, the company has concluded that the site is no longer economically viable.
In a statement issued by a spokesperson for Haleon, they stated, "Following a strategic review of our global manufacturing capabilities, we have determined that
our Maidenhead site is no longer a viable option for the manufacture of our products."
Lo's Pharmacy, a Yorkshire-based pharmacy chain is adopting a new approach to hub and spoke in a first of a kind model to be used in the UK.
The pharmacy will centralise its repeat prescription dispensing service for original packs with the support of its medication wholesaler.
The independent group, which has 25 NHS community pharmacies across Yorkshire, will install Centred Solution's Automated FLOWRx Hub product at its central dispensing
facility in Wath-Upon-Dearne, South Yorkshire.
But unlike other FLOWRx customers, who pick packs from a robotic dispensing system or internal warehouse, Lo's Pharmacy will receive patient-specific flow totes
directly from their wholesaler which can then be processed by their hub.
This workflow has not been used anywhere else in the country until now and it is a revolutionary approach to hub and spoke dispensing, showing what can be achieved
when key players decide to collaborate. It further demonstrates that there are range of variations of hub and spoke models available and accessible to independent
and multiple community pharmacies across the UK.
In a bid to amplify the role of pharmacists in clinical services and vaccination programs, the Pharmacists' Defence Association (PDA) has embarked on a
groundbreaking collaboration with Aston University.
This initiative, funded by Innovate UK Business Connect, aims to explore the feasibility and impact of integrating additional healthcare interventions within
community pharmacies.
"The Knowledge Transfer Partnership (KTP) research project represents an exciting opportunity to advance the role of pharmacists in patient care," remarked
Alison Jones, Director of Policy at PDA.
"This project will be an important part of that evolution, supporting individual pharmacists to have more opportunities to practice and so develop more fulfilling
careers."
Led by the PDA and Aston University, the project will commence imminently, focusing on the Priory Community Pharmacy in Dudley.
Viveca Biomed has launched an innovative and clinically-proven bladder support device that offers women immediate relief from stress urinary incontinence (SUI)
and provides community pharmacy contractors with a way to build a new consumer base, customer loyalty and sales margins.
The product, named 'Contrelle Activgard', has already recorded millions of sales in Scandinavia over a decade.
The company behind the UK launch is female healthcare business Viveca Biomed, founded in 2019 by Andrew Tasker who has spent 30+ years in senior roles within the OTC
and pharma industry.
Contrelle is manufactured, packed and distributed in the UK at Viveca Biomed's factory near Newcastle, with no outsourcing, and thus offering the best possible
continuity of supply.
Ahead of the launch, the company commissioned a large consumer lifestyle survey with 500 women over 40 years of age who experience bladder leaks, to reveal the extent
of its detrimental impact.
Contrelle Activgard is a safe, discrete, easy-to-use and highly effective, single-use vaginal device, designed to immediately prevent SUI rather than just deal
with the leakage.
Jhoots Group, a West Midlands based independent community pharmacy chain, has unveiled plans to expand its digital services after securing a funding worth
£8.23m from HSBC bank.
The new money will allow the groups branches to offer a digital platform for customers to request prescriptions online, enabling the implementation of a hub and
spoke dispensing system to automate prescription deliveries.
The innovation aims to reduce the burden of manual processes on pharmacists, allowing staff to use their time efficiently and support the NHS by offering vaccines
and minor ailment medicine services.
San Jhooty, chief operating officer at Jhoots Group, said: "When faced with the unprecedented challenges of the pandemic, primary and community services came
together to support the community and each other.
The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and
diagnostics.
Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy.
This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated.
The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier
and better diagnostic technologies, to medical devices.
The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.
The Pharmacists Defence Association (PDA) has welcomed the government's action of publishing 'AI Regulation White Paper' which will regulate the artificial
intelligence (AI) system used in pharmacy on Wednesday (29 March).
The Association had raised concerns about the risk of patient harm due to inappropriate use of so-called AI to include that seen in some of the pharmacy systems
undertaking clinical checks.
For some time, it has been receiving concerns from practicing pharmacists describing examples of the potentially detrimental impact of automation and online pharmacy
provision on patient safety and pharmacy practice.
As a result, it raised these concerns with regulators, Chief Pharmaceutical Officers, and parliamentarians in all four nations of the UK to urge action.
It said: "This is required not only to protect patients, but also the frontline pharmacists who could be blamed for potential harm caused by inappropriate use of so
called 'AI' systems implemented by their employer."
The PDA therefore, welcomes the announcement from the UK government that they intend to strengthen regulation of such technology, empowering existing regulators to
come up with tailored, context-specific approaches that suit the way AI is actually being used in their sectors; this will include pharmacy.
The Medicines and Healthcare products Regulatory Agency (MHRA) has been accepted as a full member of three international work-sharing partnerships.
Through these partnerships the agency said it will play vital international role in making sure medicines and medical devices are regulated safely and efficiently
worldwide,
Two of these, the International Medical Device Regulatory Forum (IMDRF) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals
for Human Use (ICH) are focused on improving the harmonisation and convergence of medicines and medical devices regulation globally.
The partnerships will also help the MHRA to share expertise with other leading organisations, support the development of regulatory guidelines and drive greater
harmonisation of regulation around the world. This will help deliver timely access to innovative medical products not just in the UK but globally.
At last Friday's Clinical Congress Conference, the NHSE Chief Pharmaceutical Officer for England at NHS England, David Webb, announced the upcoming launch
of the Pharmacy Stakeholder Forum- an initiative led by NHS England aimed to improve pharmacy professional leadership and foster collaboration within the sector.
Webb highlighted the forum's significance as a platform for driving transformative change in pharmacy leadership.
"The aim is to deliver collaboration to develop a stronger and more united voice for pharmacy professionals," Webb emphasised.
Highlighting the need to drive transformative change in pharmacy leadership, he underscored that "the overarching goal is to address key challenges facing the
pharmacy profession and chart a course for future development and innovation."
Scheduled to commence in June, the Pharmacy Stakeholder Forum will provide a space for diverse organisations and networks with a vested interest in pharmacy
professional leadership to converge.
In a stirring address at the recent conference on Pharmacy at the Westminster Health Forum, Director of NHS Services at Community Pharmacy England (CPE),
Alastair Buxton presented a stark assessment of the community pharmacy sector's challenges.
Highlighting years of financial constraints imposed by the NHS and government, Buxton warned of a sector teetering on the edge of survival.
"There have been no years of financial and operational squeezes applied by the NHS and
government to the community pharmacy sector, so as a consequence, there are a lot of pharmacies that are on the on the brink of survival -battling for survival,"
he said.
Buxton underscored the critical and indispensable role of community pharmacies in delivering essential NHS services, from dispensing medications to innovative
initiatives like the Discharge Medicine Service and Contraception Service.
The UK pharmaceutical industry experienced a substantial increase in public trust and favourability during the Covid-19 pandemic, according to a new poll.
This trend appears to be persisting with the study showing a generally favourable view of the sector.
The recent survey, conducted by Ipsos and commissioned by Association of the British Pharmaceutical Industry (ABPI), represents the third instalment in a series
that began in 2021. This ongoing study targets members of the public, healthcare professionals, and parliamentarians.
The study once again underscored a favourable perception of the sector with 67 per cent of respondents recognising that the pharmaceutical industry produces safe
and effective medicines using cutting-edge technologies. Moreover, a majority agrees that it is a highly innovative field.
Seven out of 10 people also trust the sector's readiness to address future pandemics, even as media attention on pharmaceutical companies returns to pre-pandemic
levels. However, concerns arise regarding limitations in accessing new medicines due to cost pressures.
The Association of the British Pharmaceutical Industry (ABPI) has appointed Susan Rienow, country president of Pfizer, as its vice president.
"As vice president, she will support the president, Pinder Sahota, general manager and corporate vice president of Novo Nordisk UK, in delivering his priorities.
These are improving access to medicines, delivering economic growth and helping to find solutions to big societal challenges such as climate change, AMR, and
inequalities," said ABPI in a statement.
At Pfizer, Susan leads the organisation to bring the power of innovation, data and technology together to transform healthcare and improve outcomes for patients.
She previously led Pfizer UK's vaccines business unit during the Covid-19 pandemic.
More than 5,000 vulnerable people have enrolled for the ground-breaking Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) study on life-saving antivirals.
With this the UK is now one step closer to rolling out the innovative medicines, which would help reduce the severity of symptoms and the risk of hospitalisation or death.
Success of the study would eventually help to ease pressures on the NHS.
Anyone over the age of 50 or between 18 to 49 with certain underlying health conditions can participate in the trial after receiving a positive PCR or lateral flow test result.
Titan PMR, a pioneer of cutting pharmacy technology has set up additional new team of 12 staff to cater for a deluge of independent pharmacists investing in
new businesses.
The company is utilising the opportunity that is underway as large chains look to sell off or close their community pharmacies, offering an opportunity for
pharmacists looking to provide efficient dispensing and additional services.
In January this year Lloyds Pharmacy, which was bought by a private equity firm in 2022, announced plans to close all its 237 branches inside Sainsbury's stores over
the course of 2023. Currently, more than 5,500 of around 14,000 registered pharmacy premises across the UK are owned by corporates and supermarkets.
Titan PMR - an innovative, cloud-based system which manages end-to-end pharmacy workflow - has become the preferred software platform especially amongst first time
buyers who are keen to offer new services to patients. The new team at the Bristol-based company, hired to support this sector, sees its total workforce growing to
more than 50 staff.